-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
B. Riley Comments on MiNK Therapeutics, Inc.'s Q2 2023 Earnings (NASDAQ:INKT)
B. Riley Comments on MiNK Therapeutics, Inc.'s Q2 2023 Earnings (NASDAQ:INKT)
MiNK Therapeutics, Inc. (NASDAQ:INKT – Get Rating) – Investment analysts at B. Riley issued their Q2 2023 earnings per share (EPS) estimates for shares of MiNK Therapeutics in a note issued to investors on Monday, November 14th. B. Riley analyst K. Patel expects that the company will post earnings of ($0.22) per share for the quarter. The consensus estimate for MiNK Therapeutics' current full-year earnings is ($0.84) per share.
Get MiNK Therapeutics alerts:MiNK Therapeutics (NASDAQ:INKT – Get Rating) last released its quarterly earnings data on Thursday, November 3rd. The company reported ($0.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.04.
Separately, HC Wainwright initiated coverage on MiNK Therapeutics in a research note on Wednesday, August 10th. They set a "buy" rating and a $7.00 price objective for the company.MiNK Therapeutics Stock Performance
MiNK Therapeutics stock opened at $3.07 on Tuesday. MiNK Therapeutics has a fifty-two week low of $1.09 and a fifty-two week high of $21.40. The company has a market capitalization of $103.67 million and a P/E ratio of -3.93. The stock has a 50-day simple moving average of $2.26 and a 200-day simple moving average of $1.91.
Hedge Funds Weigh In On MiNK Therapeutics
An institutional investor recently bought a new position in MiNK Therapeutics stock. First Republic Investment Management Inc. purchased a new position in MiNK Therapeutics, Inc. (NASDAQ:INKT – Get Rating) during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 81,500 shares of the company's stock, valued at approximately $172,000. First Republic Investment Management Inc. owned 0.24% of MiNK Therapeutics at the end of the most recent reporting period. 1.07% of the stock is currently owned by institutional investors.
MiNK Therapeutics Company Profile
(Get Rating)
MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials.
Read More
- Get a free copy of the StockNews.com research report on MiNK Therapeutics (INKT)
- Power Integrations Stock Can Power Your Portfolio
- Don't Chase Walmart Higher, Wait For Extra Low Prices
- Home Depot Results (and Institutions) Are A Catalyst For Lowe's?
- Agilent Remains In Buy Range Ahead Of Next Week's Q4 Report
- Three Penny Stocks Making Big Moves In November
Receive News & Ratings for MiNK Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiNK Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
MiNK Therapeutics, Inc. (NASDAQ:INKT – Get Rating) – Investment analysts at B. Riley issued their Q2 2023 earnings per share (EPS) estimates for shares of MiNK Therapeutics in a note issued to investors on Monday, November 14th. B. Riley analyst K. Patel expects that the company will post earnings of ($0.22) per share for the quarter. The consensus estimate for MiNK Therapeutics' current full-year earnings is ($0.84) per share.
水貂治療公司(納斯達克:iNKT-GET評級)-B.Riley的投資分析師在11月14日星期一發給投資者的一份報告中發佈了他們對水貂治療公司股票2023年第二季度每股收益的估計。B.Riley分析師K.Patel預計,該公司本季度每股收益將達到0.22美元。對水貂治療公司目前全年收益的普遍估計為每股0.84美元。
MiNK Therapeutics (NASDAQ:INKT – Get Rating) last released its quarterly earnings data on Thursday, November 3rd. The company reported ($0.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.04.
水貂治療公司(納斯達克代碼:iNKT-GET Rating)最近一次發佈季度收益數據是在11月3日星期四。該公司公佈了本季度每股收益(EPS)(0.19美元),比普遍預期的(0.23美元)高0.04美元。
MiNK Therapeutics Stock Performance
水貂治療公司股票表現
MiNK Therapeutics stock opened at $3.07 on Tuesday. MiNK Therapeutics has a fifty-two week low of $1.09 and a fifty-two week high of $21.40. The company has a market capitalization of $103.67 million and a P/E ratio of -3.93. The stock has a 50-day simple moving average of $2.26 and a 200-day simple moving average of $1.91.
水貂治療公司的股票週二開盤報3.07美元。水貂治療公司的股價為1.09美元,為52周低點,52周高點為21.40美元。該公司市值為1.0367億美元,市盈率為-3.93倍。該股的50日簡單移動均線切入位在2.26美元,200日簡單移動均線切入位在1.91美元。
Hedge Funds Weigh In On MiNK Therapeutics
對衝基金入股水貂治療公司
An institutional investor recently bought a new position in MiNK Therapeutics stock. First Republic Investment Management Inc. purchased a new position in MiNK Therapeutics, Inc. (NASDAQ:INKT – Get Rating) during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 81,500 shares of the company's stock, valued at approximately $172,000. First Republic Investment Management Inc. owned 0.24% of MiNK Therapeutics at the end of the most recent reporting period. 1.07% of the stock is currently owned by institutional investors.
一家機構投資者最近買入了水貂治療公司股票的新頭寸。根據第一共和國投資管理公司在第三季度購買了水貂治療公司(納斯達克:iNKT-GET評級)的新頭寸,根據該公司在最近提交給美國證券交易委員會的13F文件中。該機構投資者購買了81,500股該公司股票,價值約172,000美元。First Republic Investment Management Inc.在最近的報告期結束時擁有水貂治療公司0.24%的股份。該股目前由機構投資者持有1.07%的股份。
MiNK Therapeutics Company Profile
水貂治療公司簡介
(Get Rating)
(獲取評級)
MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials.
明克治療公司是一家臨牀階段的生物製藥公司,致力於同種異體、現成、不變的自然殺傷T(INKT)細胞療法的發現、開發和商業化,以治療癌症和其他免疫介導性疾病。它的候選產品是AGENT-797,這是一種現成的同種異體藥物,用於iNKT細胞治療和治療各種骨髓瘤疾病,目前處於第一階段臨牀試驗。
Read More
閲讀更多內容
- Get a free copy of the StockNews.com research report on MiNK Therapeutics (INKT)
- Power Integrations Stock Can Power Your Portfolio
- Don't Chase Walmart Higher, Wait For Extra Low Prices
- Home Depot Results (and Institutions) Are A Catalyst For Lowe's?
- Agilent Remains In Buy Range Ahead Of Next Week's Q4 Report
- Three Penny Stocks Making Big Moves In November
- 免費獲取StockNews.com關於水貂治療的研究報告(INKT)
- 電源整合股票可以為您的投資組合提供動力
- 不要追逐沃爾瑪更高,等待超低價格
- 家得寶的業績(和機構)是勞氏的催化劑嗎?
- 安捷倫在下週第四季度報告發布前仍在買入區間
- 三隻細價股在11月大動干戈
Receive News & Ratings for MiNK Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiNK Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受水貂治療日報的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對水貂治療和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧